Zenotech Laboratories Ltd (ZENOTECH)

Loading page…

Zenotech Laboratories Ltd (ZENOTECH) · mywealthgrid

About

Zenotech Laboratories is a micro-cap pharmaceutical company with a market cap of ₹289.2 crore, operating in pharmaceuticals and biotechnology within the healthcare sector. Recent quarterly revenue ranges ₹2.94–₹7.85 crore through standalone operations, with the company showing significant operational volatility between profitability and losses over the past two years.

Face value: ₹10

Market cap

₹256 Cr

P/E

—

P/B

2.7×

Dividend yield

ROE

-1.1%

ROCE

4.4%

Debt / equity

OPM

13%

EPS (TTM)

₹-0.2

Book value

₹15.6

52-week high

—

52-week low

—

Key insights

Company research notes and source-linked reviews

Key risks

Revenue highly volatile (₹2.94–₹7.85 Cr across recent quarters); verify whether volatility reflects seasonality, project delays, or structural headwinds in core markets.

Profitability inconsistent with operating losses in 2020 (Sep 2020 OPM −31.66%, Mar 2020 loss ₹0.03 Cr) and recovery thereafter; verify drivers of loss periods and whether structural issues persist.

ROE of only 6.01% indicates poor capital efficiency; investigate what constrains returns on deployed capital.

Micro-cap structure with zero institutional participation (FII 0%, DII 0.01%) creates liquidity and analyst-coverage gaps; stock down 19.44% over one year.

Generated analysis · source review pending

Growth drivers

Revenue recovered from ₹2.94 Cr (Sep 2020) to ₹7.85 Cr (Mar 2021); verify if growth trajectory sustains and reflects structural improvement or seasonality.

Operating margin improved from −31.66% (Sep 2020) to 32.94% (current), signaling operational stabilization; confirm drivers and assess scope for further margin expansion.

Zero debt (D/E = 0) provides financial capacity for growth investment or strategic opportunities; verify management's capital allocation and growth strategy.

Generated analysis · source review pending

2,372 historical price candles were omitted because the exchange source has not been verified.

₹42.0-1.2%1Y

Quick read

rule-based

Pros

+Almost debt-free (debt/equity 0)
+High promoter holding of 68.8% with no pledge

Cons

−Low return on equity of 4.8% (3-yr avg)

Research score

Structured signal from quality, growth, valuation and momentum.

41/100

Business quality: 32
Growth: 50
Valuation: 42

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	2	2	11	13	26	22	37	42	41	43	40
COGS	-0	-2	-1	-1	-1	0	0	0	0	1	0
Gross profit	—	—	—	—	—	—	—	—	—	42	—
	12	17	19	17	18	16	19	22	24	28	34
	-10	-13	-7	-4	9	6	17	21	17	14	5
OPM %	-483.5%	-586.3%	-65.8%	-26.9%	34.4%	28.5%	47.8%	48.8%	42.2%	32.9%	13%
Depreciation	—	—	4	4	5	6	7	7	7	7	7
Interest	8	8	3	0	1	2	1	0	0	0	0
	0	0	2	5	1	0	1	1	1	3	6
Profit before tax	-19	-20	-12	-3	11	-1	10	15	11	11	4
Tax	—	—	—	—	—	0	-12	3	3	5	5
Tax %	—	—	—	—	—	0%	-123.9%	20.1%	25.5%	47.5%	125.5%
	-19	-20	-12	-3	11	-1	22	12	8	6	-1
PAT margin %	-927.7%	-879.2%	-106.4%	-24%	41.6%	-5.4%	60.7%	27.3%	20.3%	13%	-2.7%
EPS (₹)	-5.6	-5.8	-2.5	-0.6	0.8	-0.2	3.6	1.9	1.4	0.9	-0.2
EPS adjusted (₹)	-5.6	-5.8	-1.9	-0.5	1.8	-0.2	3.6	1.9	1.4	0.9	-0.2
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	34	34	61	61	61	61	61	61	61	61	61
Reserves	-61	-100	-19	-22	-11	-13	10	21	30	35	34
	51	51	20	20	19	21	6	0	0	0	0
	39	65	19	25	17	17	17	19	16	15	16
Total equity & liabilities	64	51	82	85	86	86	94	101	106	111	111
	52	47	44	43	49	74	71	65	66	61	62
CWIP	—	2	2	17	29	2	0	5	2	4	4
Investments	—	—	—	—	—	0	0	0	0	0	0
	12	2	35	25	8	9	23	31	39	47	45
Total assets	64	51	82	85	86	86	94	101	106	111	111

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	—	—	—	—	98%	—
EBITDA margin %	-26.9%	34.4%	28.5%	47.8%	48.8%	42.2%	32.9%	13%
EBIT margin %	-59.2%	15.7%	-0.3%	28.7%	31.9%	24.8%	16.8%	-5%
PAT margin %	-24%	41.6%	-5.4%	60.7%	27.3%	20.3%	13%	-2.7%
Working capital
Receivable days	66	26	62	39	29	29	63	81
Inventory days	13	2	1	1	0	13	0	0
Payable days	—	—	44	40	58	51	1,095	39
NWC days	—	—	20	1	-30	-9	-1,032	42
Leverage
Current ratio	0.42	0.16	0.49	0.47	0.98	1.93	2.86	3.4
Debt to EBITDA	—	2.09	3.23	0.34	0	0	0	0
Debt to equity	0.52	0.38	0.43	0.08	0	0	0	0
Interest coverage	-25	6	0.2	9.1	132.8	—	—	—
Asset turnover	0.15	0.3	0.26	0.39	0.42	0.38	0.39	0.36
Return ratios
Return on assets %	-3.7%	12.6%	-1.4%	23.6%	11.5%	7.8%	5.1%	-1%
Return on capital employed %	-7.4%	11.9%	0.5%	14.9%	18%	12.6%	9.2%	4.4%
Return on equity %	-8%	21.7%	-2.5%	31.4%	14.1%	9.2%	5.8%	-1.1%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	68.84%	68.84%	68.84%	68.84%	68.84%	68.84%	68.84%	68.84%	68.84%	68.84%	68.84%	68.84%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0.98%	0.98%	0.98%	0.98%
	31.15%	31.15%	31.15%	31.15%	31.15%	31.15%	31.15%	31.15%	30.17%	30.17%	30.17%	30.17%
No. of shareholders	—	—	—	—	—	—	—	—	10,670	10,464	10,301	10,161

Promoter holding up 0 percentage points since Sep 2023.

Mr. AZADAR HUSAIN ASGHAR MEHDI KHANNon-Executive - Non Independent Director
Mr. JIGNESH ANANTRAY GORADIANon-Executive - Non Independent Director
Poly K VChief Financial Officer
Mrs. JAGRUTI PRASHANT SHETHNon-Executive - Independent Director
Mr. RAKESHCHANDRA JAGDISHPRASAD SINHANon-Executive - Non Independent Director
Mr. PREMAL HEMANT GANDHINon-Executive - Independent Director
Mr. NIKKHIL VENILAL KOTHHARINon-Executive - Independent Director
Mr. Sachin Laxmanappa GavandareChief Executive Officer
Abdul Gafoor MohammadCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Zenotech Laboratories Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results28 Jul 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

10 announcementsExport CSV

29 Aug 2026, 10:06 amCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

28 Aug 2026, 12:56 pmAGM/EGM

Notice Of 37Th Annual General Meeting To Be Held On Friday, September 25, 2026 Along With Annual Report For The FY 2025-26.

AGM PDF

28 Aug 2026, 12:50 pmOthers

Reg. 34 (1) Annual Report.

Reg. 34 (1) Annual Report PDF

24 Aug 2026, 2:20 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

22 Aug 2026, 5:33 pmAGM/EGM

Intimation Of 37Th Annual General Meeting Of Zenotech Laboratories Limited

AGM PDF

29 Jul 2026, 12:54 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

28 Jul 2026, 2:47 pmBoard Meeting

Board Meeting Outcome for Outcome Of The Board Meeting Held Today, I.E., July 28, 2026

Outcome of Board Meeting PDF

28 Jul 2026, 2:40 pmResult

Unaudited Financial Results For The Quarter Ended June 30, 2026

Financial Results PDF

Date	Category	Subject	Filing
29 Aug 2026, 10:06 am	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
28 Aug 2026, 12:56 pm	AGM/EGM AGM	Notice Of 37Th Annual General Meeting To Be Held On Friday, September 25, 2026 Along With Annual Report For The FY 2025-26.

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	—	—	—	—	98%	—
EBITDA margin %	-26.9%	34.4%	28.5%	47.8%	48.8%	42.2%	32.9%	13%
EBIT margin %	-59.2%	15.7%	-0.3%	28.7%	31.9%	24.8%	16.8%	-5%
PAT margin %	-24%	41.6%	-5.4%	60.7%	27.3%	20.3%	13%	-2.7%
Working capital
Receivable days	66	26	62	39	29	29	63	81
Inventory days	13	2	1	1	0	13	0	0
Payable days	—	—	44	40	58	51	1,095	39
NWC days	—	—	20	1	-30	-9	-1,032	42
Leverage
Current ratio	0.42	0.16	0.49	0.47	0.98	1.93	2.86	3.4
Debt to EBITDA	—	2.09	3.23	0.34	0	0	0	0
Debt to equity	0.52	0.38	0.43	0.08	0	0	0	0
Interest coverage	-25	6	0.2	9.1	132.8	—	—	—
Asset turnover	0.15	0.3	0.26	0.39	0.42	0.38	0.39	0.36
Return ratios
Return on assets %	-3.7%	12.6%	-1.4%	23.6%	11.5%	7.8%	5.1%	-1%
Return on capital employed %	-7.4%	11.9%	0.5%	14.9%	18%	12.6%	9.2%	4.4%
Return on equity %	-8%	21.7%	-2.5%	31.4%	14.1%	9.2%	5.8%	-1.1%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-5	2	-16	-14	11	6	18	21	12	9	10
	6	-1	-3	-16	-21	-5	-2	-6	-21	15	-6
	-1	-1	47	15	-3	0	-16	-6	0	0	0
Net cash flow	-0	—	—	—	—	1	-0	9	-9	25	4
Free cash flow	—	—	—	—	—	1	16	14	8	6	2
CFO / Operating profit %	—	—	—	—	127.7%	89.8%	101.1%	99.9%	68.6%	66.9%	198.8%

Zenotech Laboratories Ltd

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

Board meetings1

Announcements

Board meetings1

Ratio timeline

Quarterly record

Board and management

Not in the F&O segment

No fund holdings on record

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Return on equity

1

1